Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

pramoxine hydrochloride hydrocortisone acetate

&times

Overview

What is PROCTOFOAM?

DESCRIPTION:

Proctofoam-HC contains a synthetic corticosteroid used as an anti-inflammatory/antipruritic agent and a local anesthetic.



What does PROCTOFOAM look like?



What are the available doses of PROCTOFOAM?

Sorry No records found.

What should I talk to my health care provider before I take PROCTOFOAM?

Sorry No records found

How should I use PROCTOFOAM?

INDICATIONS AND USAGE:

®

DOSAGE AND ADMINISTRATION:


What interacts with PROCTOFOAM?

Sorry No Records found


What are the warnings of PROCTOFOAM?

Sorry No Records found


What are the precautions of PROCTOFOAM?

Sorry No Records found


What are the side effects of PROCTOFOAM?

Sorry No records found


What should I look out for while using PROCTOFOAM?

CONTRAINDICATIONS:

WARNINGS:

®


What might happen if I take too much PROCTOFOAM?

OVERDOSAGE:

PRECAUTIONS.


How should I store and handle PROCTOFOAM?

Store in a refrigerator at 2ºC to 8ºC (36ºF to 46ºF).Do not freeze or shake. Protect from light. This product contains no preservative.Store in a refrigerator at 2ºC to 8ºC (36ºF to 46ºF).Do not freeze or shake. Protect from light. This product contains no preservative.HOW SUPPLIED:NDC 0037-6822-10                10 gStore upright at controlled room temperature 20°-25°C (68°-77°F). DO NOT REFRIGERATE.HOW SUPPLIED:NDC 0037-6822-10                10 gStore upright at controlled room temperature 20°-25°C (68°-77°F). DO NOT REFRIGERATE.HOW SUPPLIED:NDC 0037-6822-10                10 gStore upright at controlled room temperature 20°-25°C (68°-77°F). DO NOT REFRIGERATE.


&times

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

CLINICAL PHARMACOLOGY:

The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man.

Pramoxine hydrochloride is a surface or local anesthetic which is not chemically related to the "caine" types of local anesthetics. Its unique chemical structure is likely to minimize the danger of cross-sensitivity reactions in patients allergic to other local anesthetics.

Non-Clinical Toxicology
CONTRAINDICATIONS:

WARNINGS:

®

Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore, it should be used with caution in patients receiving such agents.

Clindamycin is metabolized predominantly by CYP3A4, and to a lesser extent by CYP3A5, to the major metabolite clindamycin sulfoxide and minor metabolite N-desmethylclindamycin. Therefore inhibitors of CYP3A4 and CYP3A5 may increase plasma concentrations of clindamycin and inducers of these isoenzymes may reduce plasma concentrations of clindamycin. In the presence of strong CYP3A4 inhibitors, monitor for adverse reactions. In the presence of strong CYP3A4 inducers such as rifampicin, monitor for loss of effectiveness.

In vitro

Antagonism has been demonstrated between clindamycin and erythromycin. Because of possible clinical significance, the two drugs should not be administered concurrently.

PRECAUTIONS:

General:

Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings. Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application or to substitute a less potent steroid.

Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids.

Pediatric patients may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity. (see )

If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted.

In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.

ADVERSE REACTIONS:

To report SUSPECTED ADVERSE REACTIONS, contact Meda Pharmaceuticals Inc. at 866-210-5948 or FDA at 1-800-FDA-1088 or www.FDA.gov/medwatch.

&times

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

&times

Review

Rate this treatment and share your opinion


Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

This medication has worked for me.




This medication has been easy for me to use.




Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
&times

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
&times

Tips

Tips

&times

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).